deep vein thrombosis
Cardiovascular · 2012–2019
4decisions
3medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| enoxaparin Prophylaxis or treatment of deep vein thrombosis (DVT) and venous thromboembolism (VTE) prophylaxis, particularly for extended prophylaxis in high-risk… | Mar 2019 | Recommended | input received |
| nadroparin calcium Prophylaxis against deep vein thrombosis (DVT) associated with general or orthopaedic surgery, treatment of DVT, and prevention of clotting during… | Jul 2015 | Recommended with restriction | none received |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) who are at risk of developing stroke or systemic embolism… | Mar 2012 | Not recommended | unclear |
| rivaroxaban Initial treatment of confirmed acute symptomatic deep vein thrombosis (DVT) without symptomatic pulmonary embolism, and continuing treatment of DVT and… | Mar 2012 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.